Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab.

ABSTRACT:

Objective

Upon commencement of therapy for active disease, patients with systemic lupus erythematosus (SLE) show varying evolution regarding disease activity measures and patient-reported outcomes (PROs). Our objective was to identify disease evolution trajectories to gain a deeper understanding of SLE progression, ultimately improving future trial design.

Methods

Patients with ≥2 visits and available data on Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG), Physician Global Assessment (PGA), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and glucocorticoid use were included in a post hoc analysis of four randomized controlled trials of belimumab (BLISS-52, BLISS-76, BLISS-SC, EMBRACE). Gr

SUBMITTER: Parodis I 

PROVIDER: S-EPMC12048076 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature